Newron Pharmaceuticals announced that top-line results from its phase 3 STARS clinical study evaluating sarizotan in patients with Rett syndrome did not demonstrate evidence of…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.